JP2019513410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513410A5 JP2019513410A5 JP2018562399A JP2018562399A JP2019513410A5 JP 2019513410 A5 JP2019513410 A5 JP 2019513410A5 JP 2018562399 A JP2018562399 A JP 2018562399A JP 2018562399 A JP2018562399 A JP 2018562399A JP 2019513410 A5 JP2019513410 A5 JP 2019513410A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hvr
- cells
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004969 inflammatory cell Anatomy 0.000 claims 5
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 241000321096 Adenoides Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 210000002534 adenoid Anatomy 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000018529 duodenal adenocarcinoma Diseases 0.000 claims 1
- 201000005839 duodenum adenocarcinoma Diseases 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/074146 | 2016-02-19 | ||
| PCT/CN2016/074146 WO2017139975A1 (en) | 2016-02-19 | 2016-02-19 | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
| PCT/CN2017/073890 WO2017140256A1 (en) | 2016-02-19 | 2017-02-17 | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513410A JP2019513410A (ja) | 2019-05-30 |
| JP2019513410A5 true JP2019513410A5 (OSRAM) | 2020-04-02 |
| JP6972030B2 JP6972030B2 (ja) | 2021-11-24 |
Family
ID=59624718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562399A Active JP6972030B2 (ja) | 2016-02-19 | 2017-02-17 | 抗ｎ−アセチルグルコサミン及びｎ−アセチルガラクトサミンの抗体 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11446328B2 (OSRAM) |
| JP (1) | JP6972030B2 (OSRAM) |
| CN (1) | CN109071668B (OSRAM) |
| WO (2) | WO2017139975A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10202439B2 (en) | 2013-03-15 | 2019-02-12 | B&H Biotechnologies, Llc | Biological therapeutics for infection-relating disorders or conditions |
| WO2016026143A1 (en) | 2014-08-22 | 2016-02-25 | Huiru Wang | Saccharide-based biomarkers and therapeutics |
| WO2017139975A1 (en) | 2016-02-19 | 2017-08-24 | Huiru Wang | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
| CN113366021A (zh) * | 2018-10-23 | 2021-09-07 | 格雷卡迪亚尔诊断有限公司 | 糖基化Apo J特异性抗体及其用途 |
| US11357787B2 (en) * | 2019-02-18 | 2022-06-14 | Nb Health Laboratory Co., Ltd. | Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent |
| CN111234022B (zh) * | 2019-12-16 | 2024-03-22 | 江苏省药物研究所有限公司 | 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 |
| WO2025090749A1 (en) * | 2023-10-25 | 2025-05-01 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors targeting leucine rich repeat containing 15 (lrrc15) |
| CN118891290A (zh) * | 2024-04-12 | 2024-11-01 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0407586A4 (en) | 1988-09-14 | 1991-01-30 | Teijin Limited | Human monoclonal antibody and process for its preparation |
| JPH02255097A (ja) * | 1989-03-29 | 1990-10-15 | Ikuo Yamashina | 単クローン抗体ｎｎｙ１２８ |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| AU2003255544A1 (en) * | 2002-08-20 | 2004-03-11 | Biotie Therapies Corp. | Tumor specific oligosaccharide epitopes and use thereof |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| WO2005054853A2 (en) * | 2003-12-03 | 2005-06-16 | Glycominds, Ltd | Method for diagnosing diseases based on levels of anti-glycan antibodies |
| WO2008055242A2 (en) * | 2006-11-01 | 2008-05-08 | The Johns Hopkins University | Early detection of diabetes |
| US20090324617A1 (en) | 2008-01-24 | 2009-12-31 | Glykos Finland Ltd. | Cancer specific glycans and use thereof |
| US9119866B2 (en) * | 2008-04-08 | 2015-09-01 | Huiru Wang | Glycan-based drugs, therapies and biomarkers |
| CN102264765B (zh) * | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | 抗muc1抗体 |
| US8957188B2 (en) * | 2009-04-01 | 2015-02-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that bind GalNAc1-3Gal, pharmaceutical compositions and methods of using same |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| WO2011054359A2 (en) * | 2009-11-06 | 2011-05-12 | University Of Copenhagen | Method for early detection of cancer |
| CN102178686B (zh) * | 2010-01-07 | 2016-01-13 | 王慧茹 | 多糖相关疾病的药物和疫苗及免疫测定产品 |
| JP5916017B2 (ja) * | 2010-04-28 | 2016-05-11 | 塩野義製薬株式会社 | 新規なｍｕｃ１抗体 |
| CN102372773B (zh) * | 2010-08-11 | 2013-06-05 | 中国科学院生物物理研究所 | 人膀胱癌肿瘤标志物及其抗体和应用 |
| EP3101426B1 (en) * | 2010-12-16 | 2019-05-15 | National Institute of Advanced Industrial Science And Technology | Alpha2-macroglobulin from cerebrospinal fluid as an index marker for neuromyelitis optica |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US10317409B2 (en) * | 2013-03-01 | 2019-06-11 | Detroit R&D, Inc. | Glycosylation site-specific antibodies and anti-cancer compounds |
| WO2014159244A2 (en) * | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | O-GlcNAc TAU ANTIBODY AND USE THEREOF |
| ES2723883T3 (es) * | 2013-03-14 | 2019-09-03 | Merck Patent Gmbh | Inhibidores de glicosidasa |
| JP6750148B2 (ja) * | 2014-04-25 | 2020-09-02 | 公益財団法人野口研究所 | 糖鎖切断抗体の製造方法及び均一糖鎖抗体 |
| WO2016026143A1 (en) | 2014-08-22 | 2016-02-25 | Huiru Wang | Saccharide-based biomarkers and therapeutics |
| CN104267185B (zh) | 2014-09-12 | 2016-05-18 | 范飞舟 | 检测肿瘤的试剂盒及其专用识别n-乙酰氨基葡萄糖的物质 |
| CN104198707B (zh) * | 2014-09-12 | 2016-09-14 | 范飞舟 | N-乙酰氨基葡萄糖在制备检测肿瘤的试剂盒中的应用 |
| CN105177031B (zh) | 2015-06-12 | 2018-04-24 | 北京艺妙神州医疗科技有限公司 | 嵌合抗原受体修饰的t细胞及其用途 |
| WO2017139975A1 (en) | 2016-02-19 | 2017-08-24 | Huiru Wang | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
-
2016
- 2016-02-19 WO PCT/CN2016/074146 patent/WO2017139975A1/en not_active Ceased
-
2017
- 2017-02-17 JP JP2018562399A patent/JP6972030B2/ja active Active
- 2017-02-17 WO PCT/CN2017/073890 patent/WO2017140256A1/en not_active Ceased
- 2017-02-17 US US15/999,337 patent/US11446328B2/en active Active
- 2017-02-17 CN CN201780008964.2A patent/CN109071668B/zh active Active
-
2022
- 2022-08-12 US US17/819,545 patent/US12391766B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513410A5 (OSRAM) | ||
| JP2018504105A5 (OSRAM) | ||
| JP2021102633A5 (OSRAM) | ||
| JP2020510422A5 (OSRAM) | ||
| IL256871B2 (en) | Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof | |
| JP2019054802A5 (OSRAM) | ||
| RU2016111015A (ru) | НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА | |
| JP2016533721A5 (OSRAM) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2010523096A5 (OSRAM) | ||
| JP2010510809A5 (OSRAM) | ||
| JP2010516708A5 (OSRAM) | ||
| RU2017105915A (ru) | Антитела против pd-1 | |
| JP2019526622A5 (OSRAM) | ||
| JP2016534735A5 (OSRAM) | ||
| JP2013502913A5 (OSRAM) | ||
| JP2014530017A5 (OSRAM) | ||
| JP2011505875A5 (OSRAM) | ||
| JP2011526785A5 (OSRAM) | ||
| JP2013506428A5 (OSRAM) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| JP2018524300A5 (ja) | 組成物、抗体および結合性フラグメント | |
| RU2012126098A (ru) | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований | |
| JP2020522488A5 (OSRAM) | ||
| JP2011207882A5 (OSRAM) |